Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
Related stories
Micron and other chip stocks spring back to life after bruising selloff
US defence stocks tumble as investors bet on Democratic election sweep
‘I’m naturally skeptical’: I receive 10 calls a day offering me $15,000 loans at 8% interest. Is this a scam?
Colleges raced to build massive computer-science departments. Now the boom is turning to bust.
Tech stocks stumbled. Now comes a crucial week for Wall Street.
Zelenskyy, Europe and the end of Trump whispering